News
04-20-2010, 11:26 PM
Abraxis BioScience, Inc., a fully integrated biotechnology company, announced study results today that demonstrate a regimen of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) given in combination with bevacizumab (Avastin®) may have potential in the treatment of triple-negative breast cancers.
More... (http://www.news-medical.net/news/20100421/ABRAXANE-bevacizumab-combination-therapy-may-exhibit-potential-in-treatment-of-triple-negative-breast-cancers.aspx)
More... (http://www.news-medical.net/news/20100421/ABRAXANE-bevacizumab-combination-therapy-may-exhibit-potential-in-treatment-of-triple-negative-breast-cancers.aspx)